The purpose of this study is to find out whether mirdametinib in combination with palbociclib is an effective and safe treatment for people with metastatic, re…

Well Differentiated LiposarcomaDedifferentiated LiposarcomaLiposarcoma+6 more

~Estimated

~$10 – $6,250

Memorial Sloan Kettering Cancer CenterNCT06843967

Phase 1

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

The study participant has been diagnosed with non-rhabdomyosarcoma (NRSTS). Primary Objectives Intermediate-Risk * To estimate the 3-year event-free surviva…

Adipocytic NeoplasmLiposarcomaAtypical Fibroxanthoma+39 more

~Estimated

~$10 – $6,250

St. Jude Children's Research HospitalNCT06239272